GANX
Gain Therapeutics, Inc.
$1.80
-0.02 (-1.10%)
At close · Jul 10
Market Cap
$76.78M
Shares
42,654,038
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.80
Open$1.82
Day$1.74–1.82
52W$1.41–4.34
Avg vol 30d856K
Short int3.6M · 8.5% float · 1.8d
Short vol69%
Last earningsMar 23, 2026
DataMar 2021–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
−0%
below
RSI (14)
48
neutral
MACD trend
Negative
52-week position
13%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
−4%
trailing
YTD return
−44%
this year
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
1 of 42 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.46% of float · ▼ -6.7% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
42 holders — mid 3-yr range
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
−61%
Y/Y
EPS growth
+31%
Y/Y
Free cash flow
$-18.6M
Balance sheet
$20.4M
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
−0%
Neutral
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
13%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
1 of 42 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.46% of float · ▼ -6.7% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
42 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 13%
52-wk high $4
vs 200-day avg -18%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GANX
this stock
Gain Therapeutics, Inc.
|
$76.78M | -44.1% | -60.6% | — | 8.5% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GANX | -5.8% | +9.8% | -4.3% | -11.3% | -44.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -7.1% | +5.7% | -13.3% | -12.4% | -54.8% |